| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $828,377 ) |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 000 | 4 | NIH | 11/15/2024 | $828,377 |
|
| Issue Date FY: 2024 ( Subtotal = $7,330,051 ) |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | U01AI160421 | Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | 001 | 4 | NIH | 7/16/2024 | $134,320 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21MH136915 | Impact of geographic mobility on PrEP and HIV care outcomes among Latino gay, bisexual and other men who have sex with men | 000 | 1 | NIH | 8/29/2024 | $308,371 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 001 | 3 | NIH | 6/12/2024 | $73,634 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21HL175096 | Evaluating accessory cells to improve homing and engraftment efficiency of CD34+ cells from sickle cell disease patients | 000 | 1 | NIH | 8/21/2024 | $128,100 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL165202 | Transfusion-driven hyperhemolysis in sickle cell disease | 001 | 2 | NIH | 6/14/2024 | $799,330 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL124015 | Latexin function in the maintenance and regeneration of the hematopoietic system | 002 | 9 | NIH | 7/3/2024 | $427,000 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | P01HL149626 | Complications of Hemolysis and Transfusion Therapy | 000 | 5 | NIH | 7/15/2024 | $3,041,589 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL155574 | Hormetic ER Stress Regulation of Hematopoietic Stem Cell Function | 000 | 4 | NIH | 5/13/2024 | $485,415 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | U01AI160421 | Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | 000 | 4 | NIH | 5/13/2024 | $719,415 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 000 | 3 | NIH | 12/6/2023 | $828,377 |
| | 2024 | 2023 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL124015 | Latexin function in the maintenance and regeneration of the hematopoietic system | 001 | 8 | NIH | 11/16/2023 | $67,537 |
| | 2024 | 2023 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AI171525 | Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury | 001 | 2 | NIH | 1/2/2024 | $67,077 |
| | 2024 | 2023 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01DK130478 | Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells. | 001 | 3 | NIH | 11/6/2023 | $18,566 |
| | 2024 | 2023 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01DK130478 | Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells. | 001 | 3 | NIH | 11/6/2023 | $55,411 |
| | 2024 | 2023 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R56AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV - 1gp120 | 000 | 11 | NIH | 5/16/2024 | $0 |
| | 2024 | 2023 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R56AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV - 1gp120 | 000 | 11 | NIH | 5/16/2024 | $0 |
| | 2024 | 2023 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL165202 | Transfusion-driven hyperhemolysis in sickle cell disease | 000 | 1 | NIH | 3/1/2024 | $251 |
| | 2024 | 2022 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AR079766 | Autophagic regulation of inflammasome-mediated hyperactive state in living macrophages | 001 | 3 | NIH | 11/8/2023 | $176,100 |
| | 2024 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01MH118960 | Neighborhoods, Networks, and the HIV Care Continuum among HIV-infected MSM in NYC | 000 | 4 | NIH | 2/14/2024 | $0 |
| | 2024 | 2022 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120 | 000 | 10 | NIH | 5/16/2024 | $0 |
| | 2024 | 2022 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120 | 000 | 10 | NIH | 5/16/2024 | $0 |
| | 2024 | 2022 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R56HL165202 | Transfusion-driven hyperhemolysis in sickle cell disease | 000 | 1 | NIH | 3/1/2024 | -$251 |
| | 2024 | 2021 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AI153649 | Activating autophagy in filarial worms to identify novel macrofilaricides | 000 | 2 | NIH | 3/11/2024 | -$29 |
| | 2024 | 2021 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21MH124474 | A Sequential Mixed Methods Study Evaluating the Influence of Violence on HIV Care and Viral Suppression among Young Black and Latinx MSM | 000 | 2 | NIH | 2/7/2024 | -$68 |
| | 2024 | 2021 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI078314 | The development of a recombinant vaccine against human onchocerciasis | 000 | 10 | NIH | 9/18/2024 | -$86 |
| | 2024 | 2021 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI078314 | The development of a recombinant vaccine against human onchocerciasis | 000 | 10 | NIH | 9/18/2024 | -$8 |
|
| Issue Date FY: 2023 ( Subtotal = $8,144,532 ) (Continued on the next page) |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL155574 | Hormetic ER Stress Regulation of Hematopoietic Stem Cell Function | 000 | 3 | NIH | 5/11/2023 | $495,320 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R56AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV - 1gp120 | 000 | 11 | NIH | 8/25/2023 | $777,449 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL165202 | Transfusion-driven hyperhemolysis in sickle cell disease | 000 | 1 | NIH | 8/10/2023 | $815,643 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AI171525 | Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury | 001 | 2 | NIH | 6/23/2023 | $213,500 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 001 | 2 | NIH | 3/2/2023 | $92,043 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 000 | 2 | NIH | 12/28/2022 | $828,377 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | U01AI160421 | Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | 000 | 3 | NIH | 5/3/2023 | $719,415 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01DK130478 | Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells. | 001 | 3 | NIH | 7/19/2023 | $97,500 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01DK130478 | Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells. | 001 | 3 | NIH | 7/19/2023 | $338,232 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AR079766 | Autophagic regulation of inflammasome-mediated hyperactive state in living macrophages | 002 | 3 | NIH | 2/9/2023 | $85,400 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL124015 | Latexin function in the maintenance and regeneration of the hematopoietic system | 001 | 8 | NIH | 6/30/2023 | $427,000 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | P01HL149626 | Complications of Hemolysis and Transfusion Therapy | 000 | 4 | NIH | 7/1/2023 | $3,103,662 |
| | 2023 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120 | 000 | 10 | NIH | 8/16/2023 | $0 |
| | 2023 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120 | 000 | 10 | NIH | 8/16/2023 | $0 |
| | 2023 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AR079766 | Autophagic regulation of inflammasome-mediated hyperactive state in living macrophages | 001 | 3 | NIH | 2/3/2023 | $165,160 |
| | 2023 | 2021 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI078314 | The development of a recombinant vaccine against human onchocerciasis | 000 | 10 | NIH | 1/26/2023 | $0 |
| | 2023 | 2021 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | P01DK032094 | Red Cell Membrane Studies | 000 | 33 | NIH | 4/10/2023 | $0 |
| | 2023 | 2021 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI078314 | The development of a recombinant vaccine against human onchocerciasis | 000 | 10 | NIH | 1/26/2023 | $0 |
| | 2023 | 2021 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL140625 | Use of forward Genetic approaches to identify Babesia receptors | 000 | 4 | NIH | 9/27/2023 | -$7,978 |
| | 2023 | 2020 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | U01AI124260 | Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination | 000 | 5 | NIH | 3/29/2023 | -$4,250 |
|
